

Resource Summary Report

Generated by [RRID](#) on Aug 15, 2026

NIH - Rapid Access to Interventional Development

RRID:SCR_000713

Type: Tool

Proper Citation

NIH - Rapid Access to Interventional Development (RRID:SCR_000713)

Resource Information

URL:

<http://www.ninds.nih.gov/funding/nindsnotes/200707/NIH%20Rapid%20Access%20to%20Interventional%20Development>

Proper Citation: NIH - Rapid Access to Interventional Development (RRID:SCR_000713)

Description: THIS RESOURCE IS NO LONGER IN SERVICE. Documented on August 14, 2025. NIH-RAID makes available at no cost to researchers and organizations certain critical resources needed for the development of new therapeutic agents. This program, part of the Translational Research component of Reengineering the Clinical Research Enterprise, uses resources of NCI's Developmental Therapeutics Program and the National Heart Lung and Blood Institutes (NHLBI) Gene Therapy Resource Program. The services provided will depend upon the stage of the project and the strength of the preliminary data. Services available include: production, bulk supply, GMP manufacturing, formulation, development of an assay suitable for pharmacokinetic testing, and animal toxicology. Assistance also will be provided in the regulatory process, through access to independent product development planning expertise. Proposals in support of animal efficacy studies or synthesis and formulation of recombinant proteins or monoclonal antibodies will not be accepted. NIH-RAID is not a grant program. Successful projects will gain access to the governments contract resources, as well as the assistance of the NIH in establishing and implementing a product development plan. Funds to support individual projects will come both from the Roadmap and from individual Institutes, with Institutes assuming the bulk of support in the specific disease areas germane to their mission. This co-sponsorship is critical because of the resource and expertise needs and because NIH-RAID cannot support the full developmental pipeline; an Institute partnership may therefore be important for subsequent translational efforts. To obtain access to NIH-RAID resources, applications must be submitted electronically through Grants.gov using SF424. Applications are initially screened to determine whether the resources requested are appropriate for this program. Then they are reviewed by the NIH Center for Scientific Research. The results of that evaluation along with supplemental information from the lead investigator will guide final Institute and Roadmap resource allocation. The services provided will depend upon the stage of the project and the strength of the preliminary data. When a lead therapeutic agent has been selected and proposed for preclinical

development, the following services are available: For small molecules, natural products, peptides, oligonucleotides, and gene vectors: Synthesis, Scale-up production, Development of analytical methods, Development of suitable formulations, Isolation and purification of natural products, Pharmacokinetic/ADME studies including bioanalytical method development, Range-finding initial toxicology, IND-directed toxicology, Manufacture of clinical trial supplies, Product development planning and advice in IND preparation For recombinant proteins and monoclonal antibodies: Pharmacokinetic/ADME studies including bioanalytical method development, Range-finding initial toxicology, IND-directed toxicology, Product development planning and advice in IND preparation When a lead therapeutic agent has not yet been selected and proposed for preclinical development, the following services are available: For small molecules, natural products, peptides, oligonucleotides, and gene vectors: Synthesis, Development of analytical methods, Isolation and purification of natural products, Preliminary Pharmacokinetic/ADME studies, including bioanalytical method development, Preliminary toxicology For recombinant proteins and monoclonal antibodies, Preliminary Pharmacokinetic/ADME studies, including bioanalytical method development, Preliminary toxicology In some cases the NIH-RAID program will support only one or two key steps for preclinical development, while in other cases it may be possible to provide assistance with most of the development tasks needed to file an Investigational New Drug (IND) application to the Food and Drug Administration (FDA). When the NIH-RAID program does not provide all of the remaining services required for IND submission, it is expected that other resources will be in place to complete development steps not supported by NIH-RAID. Funding Resource,.

Synonyms: NIH-RAID

Resource Type: production service resource, funding resource, biomaterial analysis service, biomaterial manufacture, material analysis service, material service resource, service resource, analysis service resource

Keywords: adme, applied, biomaterial method development, clinical, pharmacology, student, toxicology

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: NIH - Rapid Access to Interventional Development

Resource ID: SCR_000713

Alternate IDs: nif-0000-00543

Old URLs: <http://nihroadmap.nih.gov/raid/>

Record Creation Time: 20220129T080203+0000

Record Last Update: 20260815T182158+0000

Ratings and Alerts

No rating or validation information has been found for NIH - Rapid Access to Interventional Development.

No alerts have been found for NIH - Rapid Access to Interventional Development.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Steinmetz KL, et al. (2009) The basics of preclinical drug development for neurodegenerative disease indications. BMC neurology, 9 Suppl 1(Suppl 1), S2.